Axovant to Present at Cowen and Company 39th Annual Health Care Conference
March 04 2019 - 7:00AM
Axovant Sciences (NASDAQ: AXGT), a clinical-stage company
developing innovative gene therapies, today announced that Pavan
Cheruvu, M.D., chief executive officer, will present at the Cowen
and Company 39th Annual Health Care Conference on March 11, 2019 at
12:00 p.m. (Eastern Time).
A live webcast will be available in the Events
section of Axovant's website at www.axovant.com. A replay will be
available for approximately 30 days following the conference.
About Axovant
Axovant Sciences is a clinical-stage gene therapy company
focused on developing a pipeline of innovative product candidates
for debilitating neurological and neuromuscular diseases. The
company’s current pipeline of gene therapy candidates targets GM1
gangliosidosis, GM2 gangliosidosis (including Tay-Sachs disease and
Sandhoff disease), Parkinson’s disease, oculopharyngeal muscular
dystrophy (OPMD), amyotrophic lateral sclerosis (ALS) and
frontotemporal dementia. Axovant is focused on accelerating product
candidates into and through clinical trials with a team of experts
in gene therapy development and through external partnerships with
leading gene therapy organizations. For more information, visit
www.axovant.com.
Contacts:
MediaMike BeyerSam Brown Inc.
(312) 961-2502mikebeyer@sambrown.commedia@axovant.com
InvestorsTricia
TruehartAxovant(631) 892-7014investors@axovant.com
Axovant Gene Therapies (NASDAQ:AXGT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Axovant Gene Therapies (NASDAQ:AXGT)
Historical Stock Chart
From Jul 2023 to Jul 2024